endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

News Briefing channel feed

Cy­tovia, Cel­lec­tis add CAR-T tar­gets to pre­ex­ist­ing cell ther­a­py pact; Bridge­Bio, Helsinn un­veil first pro­gram in R&D tie-up

4 years ago

WuXi of­fi­cial­ly opens cell and gene ther­a­py site in Philly; An­oth­er mas­sive man­u­fac­tur­ing site comes to NC

4 years ago
Cell/Gene Tx
Manufacturing

J&J un­corks long-term da­ta for Crohn's dis­ease can­di­date; Age-re­lat­ed dis­ease biotech earns Eli Lil­ly's back­ing

4 years ago

Ven­ture fund starts an­ti­body biotech in Delaware; CRO changes pri­vate eq­ui­ty hands

4 years ago

UK's Syn­thace rais­es $35M in Se­ries C; On­col­o­gy and in­flam­ma­to­ry dis­ease biotech De­ka hauls in $20M Se­ries A

4 years ago

Cas­sa­va be­ing in­ves­ti­gat­ed by un­named 'gov­ern­ment agen­cies'; Rock­et Phar­ma gives up­dat­ed da­ta on Danon dis­ease

4 years ago

Ap­pil­i's Covid-19 oral an­tivi­ral fails PhI­II tri­al; On­col­o­gy biotech Ankyra rais­es $45M in Se­ries B

4 years ago

Kaléo to pay out more than $12M in false claims case re­gard­ing high-priced ver­sion of cheap opi­oid over­dose an­ti­dote; Uro­Gen gets ready to start PhI­II can­cer tri­al

4 years ago

EQT Group ac­quires VC firm in $500M+ deal; Sanofi se­lects IPO lead­ers for 2022 API spin­out — re­port

4 years ago

Com­pass Path­ways' Phase IIb psilo­cy­bin tri­al shows re­duced de­pres­sion symp­toms

4 years ago

AI up­start grabs $40M launch round; Sanofi backs a gene ther­a­py play­er; Ax­some hits a snag at the FDA

4 years ago

San Fran biotech gets an­oth­er blow to lead drug; Swiss biotech rais­es $49 mil­lion in Se­ries A — with help from big ven­ture

4 years ago

Blue­bird bio com­pletes split in­to two com­pa­nies; BeiGene builds out Brukin­sa da­ta at ASH

4 years ago

Phase­Bio claims pos­i­tive PhII in platelet in­hi­bi­tion re­ver­sal; Tri­al soft­ware firm re­brands af­ter hack, merg­er

4 years ago

Lead­ing pro­teomics play­er gets a trio of new part­ners; GV tries to pre­vent cer­vi­cal can­cer

4 years ago

Pfiz­er ap­peals on an­ti-kick­back case; Chi­nese rare dis­ease biotech en­lists UW to re­search Duchenne gene ther­a­pies

4 years ago

Re­al-world ev­i­dence on Gilead­'s HIV com­bo Bik­tarvy con­firms high ef­fi­ca­cy; Dig­i­tal ther­a­peu­tics firm to trade on Nas­daq

4 years ago

GSK brings Johns Hop­kins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO

4 years ago

ARCH-backed SciNeu­ro kicks off search for CNS au­toan­ti­bod­ies with new deal; Mer­ck + Gilead an­nounce PhII tri­al for HIV com­bo

4 years ago

Av­enue Ther­a­peu­tics lands an FDA ad­comm for trou­bled flag­ship drug; FDA ap­proves eye in­jec­tion treat­ment for flu­id buildup

4 years ago

Lian­Bio an­nounces terms for IPO next week; NIH and White House of­fi­cials dis­cuss hy­po­thet­i­cal bio-med re­search agency

4 years ago

J&J dives deep­er in­to bis­pecifics; Spring­Works an­nounces re­search deal over Stan­ford pro­fes­sor's work

4 years ago

Sage, Bio­gen head to FDA with $3.1B de­pres­sion drug; Sana puts down $50M to tap Beam's CRISPR tech

4 years ago

Langer, Ciechanover god­fa­ther the lat­est AI up­start; Ipsen forges $446M AML de­vel­op­ment pact

4 years ago
First page Previous page 25262728293031 Next page Last page
A service from the Financial Times